Go Back   Science Forums Biology Forum Molecular Biology Forum Physics Chemistry Forum > Molecular Research Topics Forum > RNA Techniques Forum
Register Search Today's Posts Mark Forums Read

RNA Techniques Forum Post and discuss RNA methods and RNA science related topics. RNA extraction, cDNA synthesis, RNA EMSA, and other RNA protocols.

Therapeutic splice modification

Therapeutic splice modification - RNA Techniques Forum

Therapeutic splice modification - Post and discuss RNA methods and RNA science related topics. RNA extraction, cDNA synthesis, RNA EMSA, and other RNA protocols.

LinkBack Thread Tools Display Modes
Old 01-08-2009, 08:57 PM
Jon Moulton's Avatar
Points: 9,466, Level: 67 Points: 9,466, Level: 67 Points: 9,466, Level: 67
Activity: 99% Activity: 99% Activity: 99%
Join Date: May 2007
Location: Corvallis, OR, USA
Posts: 267
Thanks: 3
Thanked 15 Times in 15 Posts
Default Therapeutic splice modification

Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic Potential of Splice-Switching Oligonucleotides. Oligonucleotides. 2009 Jan 6. [Epub ahead of print]

[Only registered users see links. ]
[Only registered users see links. ]

Ryszard Kole of AVI BioPharma Inc. has published this review of therapeutic applications of splice-modifying oligos, including information about Morpholinos targeting Duchenne muscular dystrophy.

In particular he writes that the PPMO-B, a Morpholino conjugated with a cell-penetrating peptide, enters many muscles and in particular the heart where it produces 20%–30% of normal Dystrophin.

"Exon 23–skipped mRNA and restored production of dystrophin protein remained detectable for at least 2–3 months after treatment, especially in diaphragm and quadriceps, where 100% exon skipping was maintained. This suggested that the PPMO-B/ PMO is very stable in muscle tissues, because the half-life of dystrophin mRNA is only ~16 hours (Tennyson et al., 1996)."

This review explores a number of other potential therapeutic applications of splice-modifying Morpholinos, including discussions of targets such as β-globin (β-Thalassemia), SMN2 (Spinal muscular atrophy), TNFR2 and MyD88 (Inflammatory diseases), HER2 (Cancer), ClC-1 (Dystrophia myotonica type 1), ATP7A (Menkes disease), ATM (Ataxia telangiectasia), APOB (Atherosclerosis), PCCA, PCCB, and MUT (Propionic and methylmalonic acidemias).
Jon D. Moulton, Ph.D.
Gene Tools, LLC
[Only registered users see links. ]

Last edited by Jon Moulton; 01-08-2009 at 11:43 PM. Reason: add link
Reply With Quote

dmd , duchenne , modification , morpholino , splice , therapeutic

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On

Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
detect splice variants in living cell Zhong Silin Protocols and Methods Forum 5 07-14-2008 05:57 PM
bisulfite dna modification kit Wen Huang Protocols and Methods Forum 0 02-20-2008 05:45 PM
2nd Annual Neurodegenerative Disorders 2005 Ben Radford Protocols and Methods Forum 0 01-19-2005 02:10 PM
Biophysics & Schumann Resonance Consc Physics Forum 16 12-27-2004 10:45 AM
INVITATION TO ATTEND THERAPEUTIC VACCINES - NOT TRUNCATED Miriam Glaser Heston Microbiology Forum 0 01-06-2004 08:43 PM

All times are GMT. The time now is 07:05 AM.

Powered by vBulletin® Version 3.8.4
Copyright ©2000 - 2015, Jelsoft Enterprises Ltd.
Copyright 2005 - 2012 Molecular Station | All Rights Reserved
Page generated in 0.12687 seconds with 16 queries